FDA approves durvalumab combination before and after surgery for bladder cancer
- FDA approves durvalumab combination before and after surgery for bladder cancer
- Weekend breaks in dasatinib matched daily treatment for leukemia
- Community programs helped address breast cancer screening gaps
- Gene patterns predicted treatment resistance in breast cancer
- KRAS-targeting vaccines may help prevent pancreatic cancer recurrence
- A three-drug treatment showed activity in metastatic bowel cancer
- Clinic factors shaped trial access for people with advanced cancer
FDA approves durvalumab combination before and after surgery for bladder cancer
The FDA approved the immunotherapy durvalumab with the antibody-drug conjugate enfortumab vedotin before surgery, followed by durvalumab, for adults with muscle-invasive bladder cancer who cannot or will not take cisplatin. In a trial of 695 patients, median event-free survival was not reached, compared with 12.1 months after surgery alone.
Why it matters. People with muscle-invasive bladder cancer who cannot take cisplatin may have a treatment option before and after surgery. Doctors can now prescribe it.
The ASCO Post, 13 Nov 2026 · Regulatory approval | 695 patients Worth sharing · Share on X · Email a friendWeekend breaks in dasatinib matched daily treatment for leukemia
Among people starting treatment for chronic myeloid leukemia, weekend breaks led to remission in 78% at 24 months, versus 81% with daily treatment.
“The incidence of pleural or pericardial effusion appears to be reduced compared with standard-of-care continuous dosing.”
Why it matters. People starting treatment for chronic myeloid leukemia may be able to take weekends off dasatinib. Results from a large final-stage trial like this decide approvals.
Journal of Clinical Oncology, 13 Nov 2026 · Phase III human clinical trial | 289 patients Worth sharing · Share on X · Email a friendCommunity programs helped address breast cancer screening gaps
A review found that community health worker programs to promote breast cancer screening were cost-effective and increased quality-adjusted life years saved.
“At the VCU Massey Comprehensive Cancer Center, Baskin said they implemented the Alliance for Equity in Cancer Care initiative to help identify patients with SDOH barriers and to offer corresponding support services.”
Why it matters. People who face barriers to breast cancer screening may get help finding and completing screening through community health workers. Randomized trials like this are the fairest kind of test.
AACR, 13 Nov 2026 · Randomized human trial | around 693,000 people Worth sharing · Share on X · Email a friendGene patterns predicted treatment resistance in breast cancer
Researchers analyzed pretreatment tumor data from people with stage II to III breast cancer to build models predicting treatment response. In a validation group, the paclitaxel model identified 0.88 of patients with poor responses.
“Residual cancer burden (RCB) after neoadjuvant (given before surgery) chemotherapy is highly prognostic of disease-free survival (time without the cancer returning) in patients with high-risk early-stage breast cancer, and extensive residual disease (RCBIII) indicates treatment resistance.”
Why it matters. People with high-risk breast cancer may one day get treatment choices guided by patterns that predict resistance. A larger trial usually comes before approval.
JCO Precision Oncology, 13 Nov 2026 · Phase II human clinical trial | 987 patientsKRAS-targeting vaccines may help prevent pancreatic cancer recurrence
Researchers identified KRAS-targeting vaccination as a potential way to prevent pancreatic cancer from returning, though many hurdles remain.
Why it matters. People with pancreatic cancer may one day have a vaccine to help prevent it from returning.
Nature Medicine, 13 Nov 2026 · Research findingA three-drug treatment showed activity in metastatic bowel cancer
In a phase 2 study, people with metastatic bowel cancer received the antimicrobial metronidazole, the immunotherapy tislelizumab and fruquintinib. The treatment showed clinical activity with manageable side effects and reduced the targeted bacteria.
Why it matters. People with metastatic bowel cancer linked to these bacteria may benefit from a treatment that targets the bacteria alongside cancer drugs. A larger trial usually comes before approval.
Cancer Cell, 13 Nov 2026 · Phase II human clinical trialClinic factors shaped trial access for people with advanced cancer
Researchers studied adults with advanced solid cancers treated by 1,664 doctors at 107 practices. Just over 5% joined trials, and doctors’ and clinics’ practices explained more differences in enrollment than measured patient traits.
“Unlike a patient’s age or cancer type, a doctor’s trial habits and a clinic’s research support are things a health system can change,” said lead author Changchuan “Charles” Jiang, MD, MPH , Assistant Professor of Internal Medicine in the Division of Hematology and Oncology and of Health Economics, Systems and Policy in the Peter O’Donnell Jr.”
Why it matters. People with advanced cancer may have more chances to join trials if clinics strengthen research support and doctors offer more studies. It studied patient records rather than testing a treatment.
The ASCO Post, 13 Nov 2026 · Human observational study | more than 200,000 patientsDeals and stopped trials
- FDA Approves Durvalumab With Enfortumab Vedotin-ejfv for Muscle-Invasive Bladder Cancerascopost.com
- FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCCascopost.com
- FDA Approves Expanded Indication for Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBCascopost.com
- TIL Therapy for Patients With Advanced Solid TumorsTerminated · Phase I · NeogenTC · Reason given: It is due to difficulties in enrolling participants.
- A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid TumorsTerminated · Phase I · Novartis Pharmaceuticals · Reason given: Business decision and not related to safety concerns
India
Worth watching
- FDA approves durvalumab combination for muscle-invasive bladder cancerThe FDA approved immunotherapy durvalumab with the antibody-drug conjugate enfortumab vedotin before surgery, followed by durvalumab, for adults with muscle-invasive bladder cancer who cannot or will not take cisplatin. In a 695-person trial, median time without a cancer-related event was not reached, versus 12.1 months with surgery alone.
- FDA approves antibody treatment amivantamab for head and neck cancerIn a trial of 102 people with recurrent or metastatic head and neck cancer after chemotherapy and immunotherapy, the treatment shrank tumors in 42%. Among those whose tumors shrank, 56% had responses lasting at least 6 months.
- A risk score predicts outcomes of bispecific treatments for myelomaResearchers developed and independently tested a risk score for people with relapsed myeloma receiving bispecific T-cell treatments. The median time before cancer grew was 21.8 months in the low-risk group and 1.6 months in the high-risk group.
- Personalized mRNA Cancer Vaccine Reduces Melanoma Recurrence RiskResearch finding, JAMA, 13 Nov 2026
- Molecular Profiling for Precision Medicine in Adrenocortical Carcinoma: Real-World Data From the French Network ENDOCAN-COMETEResearch finding, JCO Precision Oncology, 13 Nov 2026
- When Safety Depends on Coincidence: A Near-Miss in Radium-223 Therapy Revealing Latent Vulnerabilities in Theranostics Emergency CareResearch finding, JCO Oncology Practice, 13 Nov 2026